SG11201500408VA - Extended-release formulation for reducing the frequency of urination and method of use thereof - Google Patents

Extended-release formulation for reducing the frequency of urination and method of use thereof

Info

Publication number
SG11201500408VA
SG11201500408VA SG11201500408VA SG11201500408VA SG11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA SG 11201500408V A SG11201500408V A SG 11201500408VA
Authority
SG
Singapore
Prior art keywords
urination
extended
frequency
reducing
release formulation
Prior art date
Application number
SG11201500408VA
Inventor
David A Dill
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of SG11201500408VA publication Critical patent/SG11201500408VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201500408VA 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof SG11201500408VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/030901 WO2013142197A1 (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
SG11201500408VA true SG11201500408VA (en) 2015-03-30

Family

ID=49223209

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201500408VA SG11201500408VA (en) 2012-03-19 2013-03-13 Extended-release formulation for reducing the frequency of urination and method of use thereof
SG11201500409SA SG11201500409SA (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201500409SA SG11201500409SA (en) 2012-03-19 2013-03-14 Extended-release formulation for reducing the frequency of urination and method of use thereof

Country Status (15)

Country Link
EP (2) EP2827852A4 (en)
JP (5) JP2015510928A (en)
KR (4) KR20140134333A (en)
CN (4) CN107157991A (en)
AU (4) AU2013235518B2 (en)
BR (2) BR112014020271A8 (en)
CA (2) CA2866853A1 (en)
HK (3) HK1251469A1 (en)
MX (3) MX2014011128A (en)
MY (2) MY174090A (en)
NZ (6) NZ714288A (en)
RU (3) RU2669565C2 (en)
SG (2) SG11201500408VA (en)
WO (2) WO2013142197A1 (en)
ZA (2) ZA201405862B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MX2016001030A (en) 2013-07-23 2016-10-07 Allergan Inc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist.
JP2017516832A (en) * 2014-06-06 2017-06-22 ウェルズリー ファーマスーティカルズ、エルエルシー Pharmaceutical formulations for reducing urination frequency and methods of use thereof
KR101809908B1 (en) * 2014-07-21 2018-01-25 주식회사 종근당 Pharmaceutical composition comprising 5-α reductase inhibitor
ES2923438T3 (en) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Compositions comprising low doses of desmopressin in combination with an alpha-adrenergic receptor antagonist
EP3355864A4 (en) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC Composition for reducing the frequency of urination, method of making and use thereof
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN105238124B (en) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 A kind of antibacterial mastic powder
JP6294924B2 (en) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ Vehicle travel control device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2546399A (en) * 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE10116978A1 (en) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa opiate agonists for the treatment of diseases of the bladder
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1476146A1 (en) * 2002-02-19 2004-11-17 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
IL165370A0 (en) * 2002-06-07 2006-01-15 Astellas Pharma Inc Therapeutic agent for overactive bladder
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
CN1758904A (en) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 Non-steroidal anti-inflammatory drug dosing regimen
JP2006520799A (en) * 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ， インコーポレイテッド Methods for treating lower urinary tract disorders using smooth muscle regulators and α2δ subunit calcium channel regulators
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP2400300A1 (en) * 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
TW200716140A (en) * 2005-06-17 2007-05-01 Dynamis Therapeutics Inc Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
ATE506059T1 (en) * 2005-09-02 2011-05-15 Theravida Inc THERAPY TO TREAT OVERACTIVE BLADDER
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Also Published As

Publication number Publication date
AU2013235518A1 (en) 2014-09-25
RU2016133305A3 (en) 2018-12-10
JP2015510936A (en) 2015-04-13
MX2014011129A (en) 2015-08-10
AU2013235507A1 (en) 2014-08-21
AU2017203246B2 (en) 2018-10-18
MY174090A (en) 2020-03-09
AU2013235518A2 (en) 2014-10-09
CN104302284A (en) 2015-01-21
JP2015510928A (en) 2015-04-13
RU2014142066A (en) 2016-05-10
EP2827852A1 (en) 2015-01-28
WO2013142274A1 (en) 2013-09-26
MX2019008817A (en) 2019-09-26
CN107157991A (en) 2017-09-15
EP2827852A4 (en) 2016-03-02
NZ630471A (en) 2016-04-29
KR20140134284A (en) 2014-11-21
BR112014020113A2 (en) 2017-06-20
RU2599017C2 (en) 2016-10-10
CN107789626A (en) 2018-03-13
HK1243921A1 (en) 2018-07-27
NZ714288A (en) 2016-12-23
CA2866853A1 (en) 2013-07-26
JP2018024693A (en) 2018-02-15
NZ714662A (en) 2016-08-26
AU2017203139B2 (en) 2018-07-19
ZA201406146B (en) 2016-08-31
MY175764A (en) 2020-07-08
SG11201500409SA (en) 2015-03-30
RU2016133305A (en) 2018-12-10
MX2014011128A (en) 2015-08-10
JP2016172752A (en) 2016-09-29
AU2017203139A1 (en) 2017-06-01
BR112014020113A8 (en) 2017-07-11
EP2827851A4 (en) 2015-10-14
KR20170015537A (en) 2017-02-08
NZ628079A (en) 2016-05-27
AU2017203246A1 (en) 2017-06-08
WO2013142197A1 (en) 2013-09-26
BR112014020271A2 (en) 2017-06-20
NZ718163A (en) 2017-09-29
HK1251469A1 (en) 2019-02-01
HK1204553A1 (en) 2015-11-27
KR20140134333A (en) 2014-11-21
JP2018138602A (en) 2018-09-06
RU2669565C2 (en) 2018-10-12
CA2866755A1 (en) 2013-09-26
KR20190003840A (en) 2019-01-09
NZ712594A (en) 2016-09-30
AU2013235518B2 (en) 2017-03-02
EP2827851A1 (en) 2015-01-28
RU2014142025A (en) 2016-05-10
AU2013235507B2 (en) 2017-03-23
BR112014020271A8 (en) 2017-07-11
CN104321056A (en) 2015-01-28
ZA201405862B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
IL274404A (en) Expandable body device and method of use
IL261768B (en) Devices and methods for the treatment of tissue
HK1243921A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IL232715A0 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
HK1200690A1 (en) Expandable body device and method of use
ZA201403762B (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
RS59200B1 (en) C4-monomethyl triterpenoid derivatives and methods of use thereof
EP2709562A4 (en) Tissue restraining devices and methods of use
EP2613735A4 (en) Devices and methods for the treatment of vascular defects
EP2825242A4 (en) Devices and methods for the treatment of vascular defects
EP2790709A4 (en) Hemostatic agents and methods of use
EP2938289A4 (en) Devices and methods for the treatment of vascular defects
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL261232A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
HK1249438A1 (en) Delayed release formulation for reducing the frequency of urination and method of use thereof
HK1203395A1 (en) Implantable devices and methods for the evaluation of active agent
HK1248549A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
HK1203159A1 (en) Prophylactic agent and or therapeutic agent for stress urinary incontinence
AP3759A (en) Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same